Analytical Data
-
Gene name
ACVR1B
- Application
-
Alternative Names
Activin Receptor Type-1B; Activin Receptor Type IB; ACTR-IB; Activin Receptor-Like Kinase 4; ALK-4; Serine/Threonine-Protein Kinase Receptor R2; SKR2; ACVR1B; ACVRLK4; ALK4
-
Species
Human
-
Source
HEK293
-
Tag
C- His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P36896
-
Expression Region
24-126aa
-
Protein Length
Partial
-
Molecular Weight
12.46 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACVR1B, also known as Activin A receptor type 1B, is a member of the transforming growth factor-beta (TGF-β) superfamily of receptors. This receptor plays a crucial role in various biological processes, including embryonic development, cellular differentiation, and tissue homeostasis. Dysregulation of ACVR1B has been implicated in numerous diseases, particularly in the context of cancer and fibrosis, where abnormal signaling pathways can lead to uncontrolled cell growth and tissue scarring. The study of ACVR1B recombinant protein is vital for elucidating its biological functions, understanding its role in pathophysiological conditions, and exploring its potential as a therapeutic target. Research has demonstrated that ACVR1B can modulate downstream signaling cascades, such as the Smad pathway, which is essential for mediating the effects of TGF-β ligands. By producing and characterizing recombinant ACVR1B, researchers aim to develop specific inhibitors or modulators that can interfere with its activity, offering new avenues for treatment. Additionally, the ability to produce this protein recombinantly allows for detailed structural and functional studies, contributing to our understanding of how ACVR1B interacts with its ligands and downstream effectors. Overall, the investigation into ACVR1B recombinant protein holds promise for advancing our knowledge of developmental biology and disease mechanisms, potentially paving the way for innovative therapeutic strategies in the future.
